Profile data is unavailable for this security.
About the company
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.
- Revenue in USD (TTM)2.31m
- Net income in USD-193.58m
- Incorporated1995
- Employees285.00
- LocationLexicon Pharmaceuticals Inc2445 Technology Forest Blvd, 11Th FloorTHE WOODLANDS 77381United StatesUSA
- Phone+1 (281) 863-3000
- Fax+1 (281) 863-8088
- Websitehttps://www.lexpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arcturus Therapeutics Holdings Inc | 124.53m | -107.30m | 577.69m | 180.00 | -- | 2.19 | -- | 4.64 | -4.02 | -4.02 | 4.66 | 9.81 | 0.2799 | -- | 2.08 | 691,811.10 | -24.12 | -19.66 | -31.37 | -24.90 | -- | -- | -86.16 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
| Celcuity Inc | 0.00 | -73.45m | 590.76m | 55.00 | -- | 3.87 | -- | -- | -2.79 | -2.79 | 0.00 | 4.35 | 0.00 | -- | -- | 0.00 | -41.61 | -37.32 | -44.44 | -39.16 | -- | -- | -- | -- | -- | -- | 0.2193 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
| Alumis Inc | 0.00 | -168.82m | 593.62m | 107.00 | -- | -- | -- | -- | -3.26 | -3.26 | 0.00 | 2.11 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -38.47 | -- | -- | -- |
| Olema Pharmaceuticals Inc | 0.00 | -99.34m | 596.81m | 75.00 | -- | 2.52 | -- | -- | -2.02 | -2.02 | 0.00 | 4.23 | 0.00 | -- | -- | 0.00 | -43.24 | -30.06 | -48.01 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
| Travere Therapeutics Inc | 155.72m | -415.73m | 600.66m | 380.00 | -- | 8.11 | -- | 3.86 | -5.32 | -2.00 | 2.04 | 0.9732 | 0.2116 | 1.57 | 7.04 | 409,800.00 | -56.49 | -36.95 | -71.19 | -44.77 | 94.34 | 95.92 | -266.96 | -165.79 | 2.75 | -- | 0.836 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
| Phathom Pharmaceuticals Inc | 2.59m | -246.63m | 602.91m | 452.00 | -- | -- | -- | 232.43 | -4.41 | -4.41 | 0.047 | -2.54 | 0.0104 | -- | -- | 5,738.94 | -98.55 | -83.26 | -111.44 | -93.77 | 77.14 | -- | -9,507.71 | -135,982.00 | 7.80 | -5.29 | 1.46 | -- | -- | -- | -1.96 | -- | -- | -- |
| Lexicon Pharmaceuticals Inc | 2.31m | -193.58m | 603.61m | 285.00 | -- | 1.42 | -- | 261.19 | -0.8257 | -0.8257 | 0.0098 | 1.17 | 0.008 | -- | 2.59 | 8,108.77 | -66.76 | -24.41 | -72.21 | -29.01 | 94.98 | 98.49 | -8,376.55 | -84.92 | 15.56 | -11.46 | 0.2569 | -- | 766.19 | -54.71 | -73.74 | -- | 37.68 | -- |
| GH Research PLC | 0.00 | -35.59m | 611.33m | 49.00 | -- | 2.79 | -- | -- | -0.6841 | -0.6841 | 0.00 | 4.21 | 0.00 | -- | -- | 0.00 | -14.81 | -- | -15.16 | -- | -- | -- | -- | -- | -- | -- | 0.0044 | -- | -- | -- | -58.47 | -- | -- | -- |
| Mineralys Therapeutics Inc | 0.00 | -90.80m | 617.13m | 28.00 | -- | 1.88 | -- | -- | -2.18 | -2.18 | 0.00 | 6.61 | 0.00 | -- | -- | 0.00 | -27.78 | -- | -29.11 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
| Scholar Rock Holding Corp | 0.00 | -183.26m | 617.30m | 150.00 | -- | 3.38 | -- | -- | -2.09 | -2.09 | 0.00 | 2.29 | 0.00 | -- | -- | 0.00 | -62.98 | -38.14 | -70.72 | -44.31 | -- | -- | -- | -647.95 | -- | -- | 0.2151 | -- | -100.00 | -- | -23.26 | -- | -45.61 | -- |
| Arrivent Biopharma Inc | -100.00bn | -100.00bn | 622.98m | 40.00 | -- | 1.96 | -- | -- | -- | -- | -- | 9.49 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.86 | -- | -- | -- |
| Humacyte Inc | 0.00 | -105.70m | 627.57m | 183.00 | -- | 24.00 | -- | -- | -1.01 | -1.01 | 0.00 | 0.2196 | 0.00 | -- | -- | 0.00 | -61.38 | -- | -68.92 | -- | -- | -- | -- | -- | -- | -61.50 | 0.4145 | -- | -100.00 | -- | -825.83 | -- | -- | -- |
| Zymeworks Inc | 50.46m | -125.97m | 627.86m | 275.00 | -- | 1.44 | -- | 12.44 | -1.79 | -1.79 | 0.7086 | 6.15 | 0.0874 | -- | 1.03 | 185,529.40 | -21.82 | -22.58 | -24.45 | -26.90 | -- | -- | -249.63 | -91.17 | -- | -- | 0.0002 | -- | -81.57 | 7.47 | -195.44 | -- | 3.58 | -- |
| Prime Medicine Inc | 591.00k | -204.50m | 628.96m | 234.00 | -- | 2.58 | -- | 1,064.23 | -2.17 | -2.17 | 0.0062 | 2.03 | 0.0019 | -- | -- | 2,525.64 | -65.09 | -- | -70.51 | -- | -- | -- | -34,601.86 | -- | -- | -- | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
| ProKidney Corp | 0.00 | -35.30m | 637.02m | 163.00 | -- | -- | -- | -- | -0.567 | -0.567 | 0.00 | -17.79 | 0.00 | -- | -- | 0.00 | -30.32 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | 67.17 | -- | -- | -- |
Data as of Jul 05 2024. Currency figures normalised to Lexicon Pharmaceuticals Inc's reporting currency: US Dollar USD
58.90%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Invus Public Equities Advisors LLCas of 13 May 2024 | 175.10m | 48.44% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 13.89m | 3.84% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 6.99m | 1.93% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 6.27m | 1.74% |
| Geode Capital Management LLCas of 31 Mar 2024 | 2.39m | 0.66% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.99m | 0.55% |
| Pinnacle Associates Ltd.as of 31 Mar 2024 | 1.75m | 0.48% |
| BVF Partners LPas of 31 Mar 2024 | 1.69m | 0.47% |
| Columbia Management Investment Advisers LLCas of 31 Mar 2024 | 1.42m | 0.39% |
| Cubist Systematic Strategies LLCas of 31 Mar 2024 | 1.40m | 0.39% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
